CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study.

CC-99282 plus R-CHOP in patients (pts) with previously untreated aggressive B-cell lymphoma (a-BCL): early safety and efficacy results from a phase 1b study CC-220-DLBCL-001 (NCT04884035) is an open-label, multicenter, dose-escalation and expansion trial to assess safety and preliminary efficacy of CC-99282 or CC-220 plus R-CHOP for untreated a-BCL. B Introduction: b Up to 30-40% of pts with diffuse large BCL relapse/become refractory after first-line chemo-immunotherapy with R-CHOP. [Extracted from the article]